---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-23-000102"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T08:22:05.111252+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics prices upsized 6.47M-share offering at $17.00 for ~$110M gross

## Summary
- Offering of 6,470,588 shares upsized; priced at $17.00/share; expected gross proceeds ~$110M.
- Underwriters granted 30-day option for up to 970,588 additional shares at same price.
- Net proceeds: ~$40M to repay asset-based revolving credit facility; ~$57.5M to settle securities class action (In re Myriad Genetics).
- Remainder for working capital and general corporate purposes; closing expected Nov 13, 2023.
- Goldman Sachs, Morgan Stanley, and Wells Fargo acting as joint book-running managers.

## SEC filing metadata
- accession: 0000899923-23-000102
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992323000102/0000899923-23-000102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992323000102/mygn-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-23-000102
- JSON: https://secwatch.observer/filing/0000899923-23-000102.json
- Plain text: https://secwatch.observer/filing/0000899923-23-000102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.